Henry Masur

Active 1975–2026

Also published as
HENRY MASUR
161
Papers
51,157
Citations
112
h-index
160
i10-index

Citations

Citations per year for Henry Masur1936: 1 citations1976: 1 citations1977: 1 citations1978: 3 citations1979: 4 citations1980: 6 citations1981: 8 citations1982: 29 citations1983: 94 citations1984: 163 citations1985: 166 citations1986: 180 citations1987: 240 citations1988: 207 citations1989: 195 citations1990: 154 citations1991: 148 citations1992: 196 citations1993: 133 citations1994: 125 citations1995: 112 citations1996: 128 citations1997: 102 citations1998: 165 citations1999: 151 citations2000: 156 citations2001: 139 citations2002: 155 citations2003: 122 citations2004: 193 citations2005: 198 citations2006: 217 citations2007: 245 citations2008: 262 citations2009: 263 citations2010: 247 citations2011: 199 citations2012: 214 citations2013: 173 citations2014: 206 citations2015: 186 citations2016: 184 citations2017: 139 citations2018: 118 citations2019: 489 citations2020: 570 citations2021: 583 citations2022: 574 citations2023: 585 citations2024: 1,048 citations2025: 446 citations2026: 21 citations1937–1975: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,483 citing papers, 32% of this breakdownUnited Kingdom: 809 citing papers, 5.8% of this breakdownChina: 787 citing papers, 5.6% of this breakdownFrance: 722 citing papers, 5.1% of this breakdownItaly: 581 citing papers, 4.1% of this breakdownGermany: 531 citing papers, 3.8% of this breakdownCanada: 517 citing papers, 3.7% of this breakdownAustralia: 464 citing papers, 3.3% of this breakdownSpain: 450 citing papers, 3.2% of this breakdownNetherlands: 377 citing papers, 2.7% of this breakdownBelgium: 297 citing papers, 2.1% of this breakdownSwitzerland: 295 citing papers, 2.1% of this breakdown
0%32%Other 26.5%

Fields

  • Medicine64.9%
  • Immunology and Microbiology17.3%
  • Health Professions8.2%
  • Biochemistry, Genetics and Molecular Biology5.3%
  • Nursing1%
  • Engineering0.8%
  • Other2.5%

Topics

  • Sepsis Diagnosis and Treatment5.9%
  • HIV Research and Treatment4.6%
  • Pneumocystis jirovecii pneumonia detection and treatment3.9%
  • Antifungal resistance and susceptibility3.7%
  • Fungal Infections and Studies3.1%
  • Central Venous Catheters and Hemodialysis2.8%
  • Other76%

Coauthors

All papers

Open in search
  1. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Charles D. Gomersall, Carol Hodgson, Morten Hylander Møller, Theodore J. Iwashyna, Shevin T. Jacob, Ruth Kleinpell, Michael Klompas, Younsuck Koh, Anand Kumar, Arthur Kwizera, Suzana Margareth Lobo, Henry Masur, Steven McGloughlin, Sangeeta Mehta, Yatin Mehta, Mervyn Mer, Mark Nunnally, Simon Oczkowski, Tiffany M. Osborn, Elizabeth Papathanassoglou, Anders Perner, Michael A. Puskarich, Jason A. Roberts, William D. Schweickert, Maureen A. Seckel, Jonathan Sevransky, Charles L. Sprung, Tobias Welte, Janice L. Zimmerman, Mitchell M. Levy - Critical Care Medicine 2021 cited by 5,021

  2. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christopher C. Kibbler, Dimitrios P. Kontoyiannis, Bart Jan Kullberg, Katrien Lagrou, Frédéric Lamoth, Thomas Lehrnbecher, Jürgen Loeffler, Olivier Lortholary, Johan Maertens, Oscar Marchetti, Kieren A. Marr, Henry Masur, Jacques F. Meis, C Orla Morrisey, Márcio Nucci, Luis Ostrosky‐Zeichner, Livio Pagano, Thomas F. Patterson, John R. Perfect, Zdeněk Ráčil, Emmanuel Roilides, Marcus Ruhnke, Cornelia Schaefer Prokop, Shmuel Shoham, Monica A. Slavin, David A. Stevens, George R. Thompson, José A. Vázquez, Claudio Viscoli, Thomas J. Walsh, Adilia Warris, L. Joseph Wheat, P. Lewis White, Theoklis E. Zaoutis, Peter G. Pappas - Clinical Infectious Diseases 2019 cited by 2,817

  3. Executive Summary: Surviving Sepsis Campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Charles D. Gomersall, Carol Hodgson, Morten Hylander Møller, Theodore J. Iwashyna, Shevin T. Jacob, Ruth Kleinpell, Michael Klompas, Younsuck Koh, Anand Kumar, Arthur Kwizera, Suzana M Lobo, Henry Masur, Steven McGloughlin, Sangeeta Mehta, Yatin Mehta, Mervyn Mer, Mark Nunnally, Simon Oczkowski, Tiffany M. Osborn, Elizabeth Papathanassoglou, Anders Perner, Michael A. Puskarich, Jason A. Roberts, William D. Schweickert, Maureen A. Seckel, Jonathan Sevransky, Charles L. Sprung, Tobias Welte, Janice L. Zimmerman, Mitchell M. Levy - Critical Care Medicine 2021 cited by 494

  4. Guidelines for the Prevention of Intravascular Catheter-related Infections

    Authors: , , , , , , , , , , , , , - American Journal of Infection Control 2011 cited by 4,659

  5. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

    Authors: , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 1999 cited by 856

  6. Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure

    Authors: , , , , , , , , , , , , - Clinical Infectious Diseases 2020 cited by 203

  7. Pneumocystis jiroveciiDisease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus

    Authors: , , , , , , - Clinical Infectious Diseases 2020 cited by 137

  8. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

    Authors: , , , , , , , , , , , , , - Critical Care Medicine 2004 cited by 3,344

  9. Summary of Recommendations: Guidelines for the Prevention of Intravascular Catheter-related Infections

    Authors: , , , , , , , , , , , , , - Clinical Infectious Diseases 2011 cited by 563

  10. Workforce, Workload, and Burnout Among Intensivists and Advanced Practice Providers: A Narrative Review

    Authors: , , , , , , , , , , , , , , , - Critical Care Medicine 2019 cited by 172

  11. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America

    Authors: , , , , , - 2009 cited by 1,356

  12. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection.

    Authors: , , , , , , , , , , , , , , , , , , , , , - 2000 cited by 223

  13. Considerations for Empiric Antimicrobial Therapy in Sepsis and Septic Shock in an Era of Antimicrobial Resistance

    Authors: , , - The Journal of Infectious Diseases 2020 cited by 141

  14. Infectious Diseases Society of America (IDSA) POSITION STATEMENT: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines

    Authors: , , , , , - Clinical Infectious Diseases 2017 cited by 180

  15. Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs

    Authors: , , , , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2020 cited by 127

  16. Simtuzumab treatment of advanced liver fibrosis in HIV and HCV‐infected adults: results of a 6‐month open‐label safety trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - Liver International 2016 cited by 98

  17. Surviving Sepsis Campaign

    Authors: , , , , , , , , , , , , - Critical Care Medicine 2023 cited by 92

  18. Improving Sepsis Outcomes in the Era of Pay-for-Performance and Electronic Quality Measures: A Joint IDSA/ACEP/PIDS/SHEA/SHM/SIDP Position Paper

    Authors: , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2023 cited by 33

  19. Current Epidemiology ofPneumocystisPneumonia

    Authors: , , , , , , , , - Emerging infectious diseases 2004 cited by 435

  20. Abnormalities of B-Cell Activation and Immunoregulation in Patients with the Acquired Immunodeficiency Syndrome

    Authors: , , , , , - New England Journal of Medicine 1983 cited by 1,609

  21. Pneumocystis carinii Pneumonia: A Comparison Between Patients with the Acquired Immunodeficiency Syndrome and Patients with Other Immunodeficiencies

    Authors: , , , , , , , , , , , , , , , - Annals of Internal Medicine 1984 cited by 856

  22. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the Fungi

    Authors: , , , , , - Nature 1988 cited by 791

  23. Current approaches to the diagnosis of bacterial and fungal bloodstream infections in the intensive care unit

    Authors: , - Critical Care Medicine 2012 cited by 130

  24. An Outbreak of Community-AcquiredPneumocystis cariniiPneumonia

    Authors: , , , , , , , , , , - New England Journal of Medicine 1981 cited by 1,430